Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sio Gene Therapies Inc (SIOX)

Sio Gene Therapies Inc (SIOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 34,865
  • Shares Outstanding, K 72,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,890 K
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SIOX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings $-0.05 on 02/14/23
  • Latest Earnings Date 04/02/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3100 +54.19%
on 01/10/24
0.5000 -4.40%
on 02/02/24
+0.0930 (+24.16%)
since 01/05/24
3-Month
0.2512 +90.29%
on 11/17/23
0.5000 -4.40%
on 02/02/24
+0.0881 (+22.60%)
since 11/07/23
52-Week
0.2500 +91.20%
on 09/19/23
0.5000 -4.40%
on 02/02/24
+0.0227 (+4.99%)
since 02/07/23

Most Recent Stories

More News
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Provides Corporate Update

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies to Present at the 18th Annual WORLDSymposiumâ„¢ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition

– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results

–   Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease

- Completed three successful GMP campaigns using suspension-based manufacturing process- All batches achieved target titers and have successfully completed...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis

-   Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations-   Enrollment ongoing in the registration-enabling trial...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Reorganization of R&D Group

Two new executive positions created in connection with departure of R&D Head...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene...

SIOX : 0.4780 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sio Gene Therapies Inc. is a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. Its product candidate includes AXO-AAV-GM1 and AXO-AAV-GM. Sio Gene Therapies Inc., formerly known as Axovant Gene Therapies Ltd., is...

See More

Key Turning Points

3rd Resistance Point 0.5113
2nd Resistance Point 0.4947
1st Resistance Point 0.4863
Last Price 0.4780
1st Support Level 0.4613
2nd Support Level 0.4447
3rd Support Level 0.4363

See More

52-Week High 0.5000
Last Price 0.4780
Fibonacci 61.8% 0.4045
Fibonacci 50% 0.3750
Fibonacci 38.2% 0.3455
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar